Dongmei Ji
Fudan University · The First Affiliated Hospital of Anhui Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
14
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
71
PubMed author-name match
Trials
Studies that name Dongmei Ji as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:23 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07105592 · A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaFudan University · recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT06857279 · A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaShanghai Henlius Biotech · recruiting · Carcinoma of Head and/or Neck · principal investigator
- N/ANCT06682117 · A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid TumorFudan University · recruiting · Treatment, Neoantigen, Vaccine · principal investigator
- N/ANCT06450964 · Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic DiseasesAnhui Medical University · enrolling by invitation · Mitochondrial Diseases · study chair
- Ph2NCT06437522 · A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph4NCT06195228 · A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerFudan University · recruiting · Advanced Thyroid Cancer Patients Who Received Target Therapy · principal investigator
- Ph3NCT06177301 · Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPCFudan University · recruiting · Nasopharyngeal Carcinoma · principal investigator
- Ph2NCT06006169 · A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT05924256 · A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingFudan University · active not recruiting · Advanced Salivary Gland Carcinoma · principal investigator
- Ph1/Ph2NCT05830539 · IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor PatientsInxMed (Shanghai) Co., Ltd. · completed · Locally Advanced or Metastatic Solid Tumors · principal investigator
- Ph2NCT05673577 · Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsFudan University · completed · Squamous Cell Carcinoma of Head and Neck · principal investigator
- Early Ph1NCT05587543 · Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal CarcinomaFudan University · recruiting · Nasopharyngeal Carcinoma · principal investigator
- Ph2NCT05257018 · R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS RelapseFudan University · recruiting · Diffuse Large B-cell Lymphoma · principal investigator
- Ph2NCT04512534 · Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaFudan University · recruiting · Peripheral T-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:23 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.J Clin Oncol · 2013457 citationsRCR 12.8
- Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Lancet Gastroenterol Hepatol · 201681 citationsRCR 2.6
- Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.J Hepatol · 202270 citationsRCR 5.5
- First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.Clin Cancer Res · 202269 citationsRCR 4.2
- Electrochemical Detection of a Few Copies of Unamplified SARS-CoV-2 Nucleic Acids by a Self-Actuated Molecular System.J Am Chem Soc · 202248 citationsRCR 3.9
- Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.JAMA Surg · 202447 citationsRCR 5.3
- Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.Clin Cancer Res · 202442 citationsRCR 4.9
- Effect of chitosan on renal function in patients with chronic renal failure.J Pharm Pharmacol · 199739 citationsRCR 1.7
- Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy.Medicine (Baltimore) · 201529 citationsRCR 1.7
- Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial.Aliment Pharmacol Ther · 202228 citationsRCR 2.7